AstraZeneca share price: Q1 2022 results preview
Astrazeneca Q1 results are expected to see revenue and earnings growth despite slowing Covid-19 vaccine sales.
When are the AstraZeneca results?
The AstraZeneca the biopharmaceutical company, earnings release date is scheduled for 29 April 2022. The scheduled results will cover the groups first fiscal quarter of the year quarter one (Q1) 2022 ending March 2022.
What to expect from AstraZeneca results?
Unlike competitors Pfizer and Moderna, Astrazeneca has previously (in 2021) only offered its Covid-19 vaccine for non-profit. The year 2022 will however see the group selling its vaccine at varying (to maintain affordability), but marginal profit levels. This is expected to help add to bottom lines, although sales of the preventative Covid-19 treatment is expected to wane as the ‘pandemic’ moves to ‘endemic’ stage. Take-up of the vaccine is expected to remain strong in middle income jurisdictions such as Latin America, Southeast Asia, and the Middle East.
Revenue and earnings for the group are guided to be supported by new drugs for cancer, kidney and rare diseases. Last years acquisition of Alexon will see this quarter reflecting earnings thereto not reflected in the prio year’s comparative.
Consensus estimates from Refinitiv data arrives at the following expectations for quarter two (Q2) 2021:
- Revenue $10.792 :+47.3% year on year (YoY)
- Earnings Before Interest Tax Depreciation Amortisation (EBITDA) $3.696 billion +11.2% (YoY)
- Earnings per share (EPS) $1.71 : +4.78% (YoY)
How to trade AstraZeneca results
A Refinitiv poll of 31 analysts maintain a long term average rating of ‘buy’ for AstraZeneca (as of 22 April 2022), with 8 of these analysts recommending a strong buy, 20 recommending a buy, 2 hold and 1 sell recommendation on the stock.
AstraZeneca share price: Technical Analysis View
The share price of AstraZeneca remains in a long term uptrend. In the short term we are seeing a correction of the long term uptrend from what was overbought territory.
In lieu of the primary trend still being up, our preference remains in keeping a long bias to trades on the stock. The pullback from highs sees the 9460 as a possible downside target from the move. We are looking for a bullish price reversal before the 9460 level for long entry, with 10910 the upside target.
In summary
- AstraZeneca results are scheduled for release on 29 April 2022
- Q2 2022 revenue of $10.792 : +47.3% (YoY) expected
- Q1 2022 EBITDA of $3.696 billion : +11.2% (YoY) expected
- EPS of $1.71 : +4.98 (YoY) is expected
- The average broker rating for AstraZeneca is ‘buy’
- The share price of AstraZeneca is currently in a short term correction of a longer term uptrend
IGA, may distribute information/research produced by its respective foreign affiliates within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.
The information/research herein is prepared by IG Asia Pte Ltd (IGA) and its foreign affiliated companies (collectively known as the IG Group) and is intended for general circulation only. It does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. You should take into account your specific investment objectives, financial situation, and particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit.
No representation or warranty is given as to the accuracy or completeness of this information. Consequently, any person acting on it does so entirely at their own risk. Please see important Research Disclaimer.
Please also note that the information does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. Any views and opinions expressed may be changed without an update.
Seize a share opportunity today
Go long or short on thousands of international stocks.
- Increase your market exposure with leverage
- Get spreads from just 0.1% on major global shares
- Trade CFDs straight into order books with direct market access
Live prices on most popular markets
- Forex
- Shares
- Indices
See more forex live prices
See more shares live prices
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.
See more indices live prices
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 20 mins.
